Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.52 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199084 | 0.91 | IDO1 (0.50) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL28327420 | 0.90 | IDO1 (0.50) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL20090573 | 0.88 | IDO1 (0.54) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL20653587 | 0.88 | IDO1 (0.54) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL30141305 | 0.87 | IDO1 (0.67) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL20090679 | 0.87 | IDO1 (0.67) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL23066851 | 0.87 | IDO1 (0.55) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL20090569 | 0.87 | IDO1 (0.55) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL28961111 | 0.87 | IDO1 (0.51) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL20199121 | 0.87 | IDO1 (0.52) | IDO1TDO2IDO2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018095432-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASE | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-05-31 | — | — | WO | disclosed |